PMID- 10521733
OWN - NLM
STAT- MEDLINE
DA  - 19991118
DCOM- 19991118
LR  - 20071114
IS  - 0002-9378 (Print)
IS  - 0002-9378 (Linking)
VI  - 181
IP  - 4
DP  - 1999 Oct
TI  - A randomized trial of conjugated group B streptococcal type Ia vaccine in a
      rabbit model of ascending infection.
PG  - 803-8
AB  - OBJECTIVE: Maternal vaccination may become a central strategy in the prevention
      of early-onset group B Streptococcal sepsis. Unlike earlier group B streptococcal
      polysaccharide vaccines that were poorly immunogenic, newer vaccines conjugated
      to tetanus toxoid have been developed and have improved immunogenicity. We sought
      to evaluate a conjugated vaccine using our rabbit model of ascending infection.
      STUDY DESIGN: Rabbit does were randomized to receive either conjugated group B
      streptococcal type Ia (Ia-tetanus toxoid) or conjugated group B streptococcal
      type III (III-tetanus toxoid) vaccine. Does were vaccinated 7 days before
      conception and 7 and 21 days after conception. On days 28 to 30 of a 30-day
      gestation, does were inoculated intracervically with 10(6) colony-forming units
      of type Ia group B Streptococcus. Labor was induced if does were undelivered
      after 72 hours. Does were observed up to 7 days after inoculation. Offspring were
      observed up to 4 days. We obtained maternal cultures from the uterus, peritoneum,
      and blood and offspring cultures from the mouth, anus, and blood. Antibody levels
      were also determined. RESULTS: Offspring survival was significantly improved in
      the group receiving Ia-tetanus toxoid (P =.047). Outcomes such as maternal sepsis
      and severe illness, although not reaching statistical significance, showed a
      trend toward improved outcomes in the Ia-tetanus toxoid group. CONCLUSIONS: This 
      is the first study to evaluate the conjugated group B streptococcal vaccine by
      using any model of ascending infection. The Ia-tetanus toxoid vaccine led to
      improved survival and was immunogenic but fell short of its expected efficacy in 
      preventing ascending group B streptococcal disease under these experimental
      conditions.
AD  - Department of Obstetrics and Gynecology, University of Colorado Health Sciences
      Center, Denver, Colorado, USA.
FAU - Davies, J K
AU  - Davies JK
FAU - Paoletti, L C
AU  - Paoletti LC
FAU - McDuffie, R S
AU  - McDuffie RS
FAU - Madoff, L C
AU  - Madoff LC
FAU - Lee, S
AU  - Lee S
FAU - Eskens, J
AU  - Eskens J
FAU - Gibbs, R S
AU  - Gibbs RS
LA  - eng
GR  - AI 25152/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - UNITED STATES
TA  - Am J Obstet Gynecol
JT  - American journal of obstetrics and gynecology
JID - 0370476
RN  - 0 (Antibodies, Bacterial)
RN  - 0 (Bacterial Vaccines)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Opsonin Proteins)
RN  - 0 (Polysaccharides, Bacterial)
RN  - 0 (Tetanus Toxoid)
RN  - 0 (Vaccines, Conjugate)
RN  - 84280-28-4 (streptococcal polysaccharide Ia group B)
SB  - AIM
SB  - IM
MH  - Animals
MH  - Animals, Newborn/microbiology
MH  - Antibodies, Bacterial/blood
MH  - Bacteremia
MH  - *Bacterial Vaccines/immunology
MH  - Drug Evaluation, Preclinical
MH  - Female
MH  - Gestational Age
MH  - Immunoglobulin G/blood
MH  - Opsonin Proteins
MH  - Peritoneum/microbiology
MH  - Polysaccharides, Bacterial/*immunology
MH  - Pregnancy
MH  - Rabbits
MH  - Random Allocation
MH  - Streptococcal Infections/microbiology/*prevention & control
MH  - Streptococcus agalactiae/*immunology/isolation & purification
MH  - *Tetanus Toxoid/immunology
MH  - Uterus/microbiology
MH  - Vaccines, Conjugate/immunology
EDAT- 1999/10/16
MHDA- 1999/10/16 00:01
CRDT- 1999/10/16 00:00
AID - S0002937899005803 [pii]
PST - ppublish
SO  - Am J Obstet Gynecol. 1999 Oct;181(4):803-8.